Raul R. Silva, MDChief Science Officer
Raul R. Silva, MD is a Co-Founder of Cingulate Therapeutics and serves as the CSO. He served as Associate Professor and Vice Chairman of Child and Adolescent Psychiatry at New York University School of Medicine in New York City. Prior to that, he was the Executive Director of Rockland Children’s Psychiatric Center. He also served as the Deputy Director in the Division of Child and Adolescent Psychiatry at Bellevue Hospital Center, also in New York City. Dr. Silva is board certified in general, child and adolescent psychiatry.
Dr. Silva has authored/coauthored over 125 publications and presented at grand rounds and national meetings on over 120 occasions. He has been Principal Investigator and Co-Investigator for 21 research projects in his field.
Dr. Silva received his Doctor of Medicine degree from Ross University. He completed his fellowship in child and adolescent psychiatry at Columbia University’s St. Luke’s/Roosevelt Hospital Center where he became the director of service and residency training director. Dr. Silva completed a psychopharmacology research fellowship at New York University Medical Center.
Craig S. Gilgallon, Esq.General Counsel
Craig S. Gilgallon is a Co-Founder of Cingulate Therapeutics and serves as General Counsel. Mr. Gilgallon helped to launch and establish Pawar Gilgallon & Rudy, LLC as well as currently serving as Managing Partner.
Mr. Gilgallon has over ten years of experience in transactional and corporate law. He has a significant amount of leadership and transactional experience with numerous startup companies, and began working with Cingulate Therapeutics in 2012. As general counsel, he directs and manages all aspects of the company’s legal needs and corporate governance.
Mr. Gilgallon received a B.A. from Ithaca College and received his Juris Doctorate from the Thomas Jefferson School of Law.
Patrick Gallagher, MBA, CFADirector
Pat Gallagher is a Co-Founder of Cingulate Therapeutics and serves as a member of the Board of Directors.
Mr. Gallagher is an accomplished Capital Markets Executive, Advisor, and Investor with a distinguished record of success in both the public and private markets.
He has nearly 20 years of experience on Wall Street and extensive expertise in alternative investments, capital markets, and marketing. He is a founding partner and was CEO of BDR Research Group, LLC, a healthcare focused institutional research boutique specialized in providing services for clients in the healthcare investing, financing, and operations areas. Prior, Mr. Gallagher worked for investment and research firms Kidder Peabody, Paine Webber and New Vernon Associates.
Mr. Gallagher currently advises Kinex Pharmaceuticals, a privately held biotech with unique solutions for the treatment of cancer and immunomodulatory diseases, on business development, commercial and financial considerations. He is a co-founder of GCC Partners, a private equity and advisory firm focused on healthcare, energy and industrials.
Arthur B. Straughn, PharmDDirector
Art Straughn, PharmD is a Co-Founder of Cingulate Therapeutics and serves as a member of the Board of Directors.
During his 40 years as Professor and Director of the Drug Research Laboratory in the Department of Pharmaceutical Sciences at the College of Pharmacy, University of Tennessee, Dr. Straughn was responsible for the design and conduct of over 200 clinical trials to evaluate drug formulations for effectiveness and safety.
His career has provided him ample opportunity to consult with numerous pharmaceutical companies in helping them develop innovative drug formulations with unique drug delivery properties. More recently he has served as an expert witness in litigations involving patent issues relative to new drug formulations.
Dr. Straughn received his BS in Pharmacy from the University of North Carolina in 1972 and his Doctor of Pharmacy from the University of Tennessee in 1974.